Replimune Group Inc (REPL)
6.46
+0.31
(+5.04%)
USD |
NASDAQ |
Apr 26, 15:18
Replimune Group Research and Development Expense (Quarterly): 42.85M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 42.85M |
| September 30, 2023 | 49.10M |
| June 30, 2023 | 40.44M |
| March 31, 2023 | 37.95M |
| December 31, 2022 | 30.26M |
| September 30, 2022 | 28.83M |
| June 30, 2022 | 29.48M |
| March 31, 2022 | 21.74M |
| December 31, 2021 | 19.35M |
| September 30, 2021 | 19.90M |
| June 30, 2021 | 18.55M |
| March 31, 2021 | 16.22M |
| December 31, 2020 | 14.32M |
| September 30, 2020 | 14.05M |
| Date | Value |
|---|---|
| June 30, 2020 | 12.16M |
| March 31, 2020 | 11.19M |
| December 31, 2019 | 11.95M |
| September 30, 2019 | 8.168M |
| June 30, 2019 | 7.457M |
| March 31, 2019 | 5.413M |
| December 31, 2018 | 7.857M |
| September 30, 2018 | 4.962M |
| June 30, 2018 | 3.936M |
| March 31, 2018 | 4.503M |
| December 31, 2017 | 3.573M |
| September 30, 2017 | 3.149M |
| June 30, 2017 | 2.291M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.457M
Minimum
Jun 2019
49.10M
Maximum
Sep 2023
22.84M
Average
19.35M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Esperion Therapeutics Inc | 17.74M |
| SI-BONE Inc | 4.162M |
| Gossamer Bio Inc | 29.97M |
| Olema Pharmaceuticals inc | 25.87M |
| NovaBay Pharmaceuticals Inc | 0.004M |